Shire Pharmaceuticals
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
-
Shire Submits INTUNIV (Guanfacine Extended Release) Marketing Authorisation Application To European Medicines Agency
3/27/2014
-
Shire Pharmaceuticals Recalls A Batch Of Gaucher Disease Drug VPRIV®
3/17/2014
-
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry
2/27/2014
-
Shire plc's Massachusetts Facility Wins FDA OK To Manufacture Gaucher Disease Drug
2/14/2014
-
Shire plc Delivers Double Digit Product Sales Growth And 23% Increase In Non GAAP Earnings Per ADS
2/13/2014
-
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials
2/7/2014
-
Susan Kilsby To Succeed Matthew Emmens As Chairman Of Shire
1/23/2014
-
With Dermagraft Sale, Shire plc Jettisons Business Acquired 3 Years Ago
1/22/2014
-
Shire plc Extends Tender Offer For ViroPharma Incorporated, Acceptances Up To 76 Percent
12/27/2013
-
Hart-Scott-Rodino Waiting Period Expires for Shire's Acquisition Of ViroPharma Incorporated
12/11/2013
-
Shire plc's New Eye Drug, Lifitegrast, Disappoints In Pivotal Trial
12/6/2013
-
Shire plc to Reorg, Set to Axe 180 UK R&D Jobs
11/7/2013
-
Shire plc Release: Strong Third Quarter and Increased Non GAAP Earnings Expectations
10/24/2013
-
Shire plc Tries to Sell Its ADHD Pill in Europe, But Will Anyone Pay Attention?
10/3/2013
-
arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire Pharmaceuticals
9/19/2013
-
ViroPharma Incorporated Said to Hire Goldman, Sachs & Co. Amid Sanofi (France), Shire plc Interest
9/16/2013
-
Shire plc to Present at the Bank of America Merrill Lynch Global Health Care Conference
9/12/2013
-
Shire plc to Present at the Morgan Stanley Global Healthcare Conference
9/6/2013
-
Shire plc and Shire Pharmaceuticals Extends Existing Rare Genetic Disease Pact
8/23/2013
-
Shire plc Launches Educational Resource for People Living With Diabetes and Their Caregivers
8/7/2013